359 related articles for article (PubMed ID: 18472254)
21. Development of a novel formulation containing poly(d,l-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir.
Duvvuri S; Janoria KG; Mitra AK
J Control Release; 2005 Nov; 108(2-3):282-93. PubMed ID: 16229919
[TBL] [Abstract][Full Text] [Related]
22. Biodegradable triblock copolymer microspheres based on thermosensitive sol-gel transition.
Kwon YM; Kim SW
Pharm Res; 2004 Feb; 21(2):339-43. PubMed ID: 15032317
[TBL] [Abstract][Full Text] [Related]
23. Stability of proteins encapsulated in injectable and biodegradable poly(lactide-co-glycolide)-glucose millicylinders.
Kang J; Lambert O; Ausborn M; Schwendeman SP
Int J Pharm; 2008 Jun; 357(1-2):235-43. PubMed ID: 18384984
[TBL] [Abstract][Full Text] [Related]
24. Sustained-release delivery of octreotide from biodegradable polymeric microspheres.
Rhee YS; Sohn M; Woo BH; Thanoo BC; DeLuca PP; Mansour HM
AAPS PharmSciTech; 2011 Dec; 12(4):1293-301. PubMed ID: 21948321
[TBL] [Abstract][Full Text] [Related]
25. Co-effect of aqueous solubility of drugs and glycolide monomer on in vitro release rates from poly(D,L-lactide-co-glycolide) discs and polymer degradation.
Kim JM; Seo KS; Jeong YK; Hai BL; Kim YS; Khang G
J Biomater Sci Polym Ed; 2005; 16(8):991-1007. PubMed ID: 16128233
[TBL] [Abstract][Full Text] [Related]
26. Conformational stability of a model protein (bovine serum albumin) during primary emulsification process of PLGA microspheres synthesis.
Kang F; Singh J
Int J Pharm; 2003 Jul; 260(1):149-56. PubMed ID: 12818819
[TBL] [Abstract][Full Text] [Related]
27. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems.
Patel RB; Carlson AN; Solorio L; Exner AA
J Biomed Mater Res A; 2010 Aug; 94(2):476-84. PubMed ID: 20186771
[TBL] [Abstract][Full Text] [Related]
28. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
29. Utilization of poly(DL-lactide-co-glycolide) nanoparticles for preparation of mini-depot tablets by direct compression.
Murakami H; Kobayashi M; Takeuchi H; Kawashima Y
J Control Release; 2000 Jun; 67(1):29-36. PubMed ID: 10773326
[TBL] [Abstract][Full Text] [Related]
30. Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation.
Ahmed TA; Alharby YA; El-Helw AR; Hosny KM; El-Say KM
Drug Des Devel Ther; 2016; 10():405-15. PubMed ID: 26855565
[TBL] [Abstract][Full Text] [Related]
31. PLGA implants: How Poloxamer/PEO addition slows down or accelerates polymer degradation and drug release.
Hamoudi-Ben Yelles MC; Tran Tan V; Danede F; Willart JF; Siepmann J
J Control Release; 2017 May; 253():19-29. PubMed ID: 28284831
[TBL] [Abstract][Full Text] [Related]
32. Preparation, characterization, and in vitro evaluation of physostigmine-loaded poly(ortho ester) and poly(ortho ester)/poly(D,L-lactide-co-glycolide) blend microspheres fabricated by spray drying.
Wang L; Chaw CS; Yang YY; Moochhala SM; Zhao B; Ng S; Heller J
Biomaterials; 2004 Jul; 25(16):3275-82. PubMed ID: 14980422
[TBL] [Abstract][Full Text] [Related]
33. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems.
Luan X; Bodmeier R
J Control Release; 2006 Jan; 110(2):266-272. PubMed ID: 16300851
[TBL] [Abstract][Full Text] [Related]
34. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.
Mehta AK; Yadav KS; Sawant KK
Curr Drug Deliv; 2007 Jul; 4(3):185-93. PubMed ID: 17627492
[TBL] [Abstract][Full Text] [Related]
35. Analysis of initial burst in PLGA microparticles.
Allison SD
Expert Opin Drug Deliv; 2008 Jun; 5(6):615-28. PubMed ID: 18532918
[TBL] [Abstract][Full Text] [Related]
36. In-situ forming PLGA implants: Towards less toxic solvents.
Ramos F; Willart JF; Neut C; Agossa K; Siepmann J; Siepmann F
Int J Pharm; 2024 May; 657():124121. PubMed ID: 38621617
[TBL] [Abstract][Full Text] [Related]
37. Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation.
Wang F; Blanco E; Ai H; Boothman DA; Gao J
J Pharm Sci; 2006 Oct; 95(10):2309-19. PubMed ID: 16883563
[TBL] [Abstract][Full Text] [Related]
38. Influence of PLGA End Groups on the Release Profile of Dexamethasone from Ocular Implants.
Saraf I; Kushwah V; Alva C; Koutsamanis I; Rattenberger J; Schroettner H; Mayrhofer C; Modhave D; Braun M; Werner B; Zangger K; Paudel A
Mol Pharm; 2023 Feb; 20(2):1307-1322. PubMed ID: 36680524
[TBL] [Abstract][Full Text] [Related]
39. Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray-drying.
Quaglia F; De Rosa G; Granata E; Ungaro F; Fattal E; Immacolata La Rotonda M
J Control Release; 2003 Jan; 86(2-3):267-78. PubMed ID: 12526823
[TBL] [Abstract][Full Text] [Related]
40. Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants.
Blanco D; Alonso MJ
Eur J Pharm Biopharm; 1998 May; 45(3):285-94. PubMed ID: 9653633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
